Clinical trials: Recurrent Tumor
Breast Neoplasms
Post-Treatment Surveillance in Breast Cancer: Bringing CER to the Alliance
Nearly three million living women have survived breast cancer. Physicians rely on clinical practice guidelines to make decisions on follow-up care.
- Trial name
- NCT02171078
- Where
- United States
- Volunteers
- 34,359 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer
Trastuzumab in Treating Patients With Prostate Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00003740
- Testing
- trastuzumab
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Refractory or Recurrent Ascites
ALFApump System Versus Standard of Care in Ascites Treatment
This is a multicentre, open, randomised, and controlled trial conducted in sixty (60) patients diagnosed with refractory or recurrent ascites.
- Trial name
- NCT01528410
- Testing
- ALFApump removal of ascites, Large volume paracentesis for removal of ascites
- Where
- 7 sites in Austria, France and 3 more
- Volunteers
- 58 people
- Sponsor
- Sequana Medical N.V.
Relapsed/Refractory Leukemia
Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL)
This is a multicenter open-label phase II trial of trastuzumab in patients with HER2 positive B-ALL in relapse, or with refractory disease.
- Trial name
- NCT00724360
- Testing
- Herceptin (trastuzumab)
- Where
- 8 sites in France
- Volunteers
- 15 people
- Sponsor
- Nantes University Hospital
Fear of Cancer Recurrence
The Effect of Metacognition-based, Manualized Intervention on Fear of Cancer Recurrence
The primary aim of this study is to assess the effect of ConquerFear, a metacognition-based manualized intervention on fear of cancer recurrence, using the randomized controlled trial approach, among Chinese patients newly…
- Trial name
- NCT04568226
- Testing
- ConquerFear Intervention, Active control: Basic Cancer Care
- Where
- 6 sites in Hong Kong
- Volunteers
- 177 people
- Sponsor
- The University of Hong Kong
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
Drugs used in chemotherapy, such as 3-AP and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer, Stage IV Ovarian Epithelial Cancer
- Trial name
- NCT00081276
- Testing
- triapine, cisplatin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Low Back Pain, Low Back Pain, Recurrent
A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain
The purpose of this study is to compare the safety and effectiveness of different doses of JNJ-42160443 with placebo in the treatment of chronic, moderate to severe low back pain patients with a diagnosis of chronic low back pain.
- Trial name
- NCT00973024
- Testing
- JNJ-42160443 3 mg, JNJ-42160443 1 mg, JNJ-42160443 6 mg/3mg
- Where
- 60 sites in United States, Belgium and 2 more
- Volunteers
- 389 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Glioblastoma
Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma
This study is evaluating a combination of drugs called sirolimus and vandetanib to treat glioblastoma. Sirolimus has been approved for use in patients who undergo organ transplants.
- Trial name
- NCT00821080
- Testing
- Sirolimus, Vandetanib
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Massachusetts General Hospital
Epithelial Ovarian Carcinoma
Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma
The purpose of this study is to determine whether DCVAC/OvCa added to chemotherapy may result in prolongation of Overall Survival (OS).
- Trial name
- NCT02107378
- Testing
- DCVAC/OvCa, Standard of Care (Paclitaxel or topotecan or doxorubicin)
- Where
- 12 sites in Czechia, Germany and 1 more
- Volunteers
- 22 people
- Sponsor
- SOTIO a.s.
Breast Cancer
Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating women with previously treated…
- Trial name
- NCT00706615
- Testing
- Ad-sig-hMUC-1/ecdCD40L vaccine
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Fallopian Tubes Cancer, Ovarian Cancer
Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab
The immune system of the body has the ability to fight and eliminate infections and cancers. Immune treatments, such as in this study, seek to teach the immune system to find and destroy cancer cells.
- Conditions
- Fallopian Tubes Cancer, Ovarian Cancer, Peritoneal Cancer
- Trial name
- NCT01223235
- Testing
- bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adenocarcinoma of the Prostate, Stage I Prostate Cancer
Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Specialized radiation therapy, such as intensity-modulated radiation therapy, that delivers a high dose of radiation directly…
- Conditions
- Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer
- Trial name
- NCT01117935
- Testing
- intensity modulated external beam radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Virginia Commonwealth University
Brain Tumor, Brain Metastases
Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases
Purpose: The primary objective of this study is to determine if chemotherapy with carboplatin and temozolomide significantly affects the response rates, or size of disease, in patients with brain metastases, originating from…
- Trial name
- NCT00362817
- Testing
- carboplatin, temozolomide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
This phase I trial tests the safety, side effects, and best dose of a personalized vaccine (tumor membrane vesicle or TMV vaccine) by itself and in combination with checkpoint inhibitor (pembrolizumab or ipilimumab) in treating…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT06324240
- Testing
- Ipilimumab, Pembrolizumab, Vaccine Therapy
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Emory University
Cervical Cancer, Endometrial Cancer
CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Cervical Cancer, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT00610740
- Testing
- topical gemcitabine hydrochloride, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Wheezy Bronchitis, Recurrent Bronchitis
Tolerance and Effect of a Prophylactical Treatment With Ivy Leaves Dry Extract in Recurrent Wheezy Bronchitis
To evaluate the effect of a prophylactical therapy with a cough medicine containing ivy leaves dry extract on the frequency of recurrent wheezy bronchitis in toddlers, on the duration of the bronchitis episodes, on the severity…
- Trial name
- NCT02045550
- Testing
- Prospan Syrup
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Technische Universität Dresden
Radiotherapy Side Effect, Locoregional Recurrence
RCT Comparing 2 Radiotherapy HypoFractionation Schedules In Breast Cancer Patients
This is a prospective randomized Phase III trial to assess efficiency of two post mastectomy hypofractionation schedules (40 Gy /15 fx / 3 weeks, 5 days per week VS 28.5 Gy delivered in 5 once-weekly fractions of 5.7 Gy each…
- Trial name
- Breastcancer (NCT04550910)
- Testing
- Hypofractionation Schedules for Breast Cancer patients after mastecomy
- Where
- Egypt
- Volunteers
- 166 people
- Sponsor
- National Cancer Institute, Egypt
Immune Deficiencies
Detection and Characterization of Infections and Infection Susceptibility
This screening study will examine the causes of immune disorders affecting white blood cells, which defend against infections and will try to develop better means of diagnosis and treatment of these immune disorders.
- Trial name
- NCT00404560
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Biliary Tract Neoplasm
Study of Oxaliplatin, Irinotecan, and S-1 in Biliary Tract Cancer
This study will conduct a phase II study of triple combination with oxaliplatin, irinotecan, and S-1 as the first-line chemotherapy in patients with advanced biliary tract cancer.
- Trial name
- NCT02527824
- Testing
- Oxaliplatin, Irinotecan, S-1
- Where
- South Korea
- Volunteers
- 31 people
- Sponsor
- Hallym University Medical Center
Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory
Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL
This is a prospective, single center, single arm, open label study of zanubrutinib, lenalidomide in combination with Rituximab-ICE for treatment of relapsed/refractory diffuse large B-cell lymphoma.
- Trial name
- NCT06033820
- Testing
- ZR2-ICE
- Where
- China
- Volunteers
- 20 people
- Sponsor
- RenJi Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.